Cost-Effectiveness Analysis of Exenatide Twice Daily (BID) Versus Insulin Glargine Once Daily (QD) as Add-On Therapy in Chinese Patients With Type 2 Diabetes Mellitus Inadequately Controlled by Oral Therapies

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.2105
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search